Clinical Trials Logo
  1. Home
  2. Anemia of Chronic Kidney Disease
  3. NCT01971164

Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease

Anemia of Chronic Kidney Disease Clinical Trial

Official title:
Randomized, Single-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTZ-951 Administered Once Daily for 15 Days in Anemic Subjects With End-stage Renal Disease

Clinical Trial Summary

The purpose of this study is to determine the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of sequential ascending doses of JTZ-951 administered for 15 days in anemic subjects with end-stage renal disease (ESRD) receiving hemodialysis.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01971164
Study type Interventional
Source Akros Pharma Inc.
Contact
Status Completed
Phase Phase 1
Start date May 2013
Completion date July 2014
View Details
See also
  Status Clinical Trial Phase
Completed NCT03325621 - Phase 2a Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients Phase 1/Phase 2
Completed NCT02198495 - Comparison Study of Two Iron Compounds for Treatment of Anemia in Hemodialysis Patients Phase 4
Suspended NCT03193073 - Anemia Correction and Fibroblast Growth Factor 23 Levels in Chronic Kidney Disease , and Renal Transplant Patient N/A
Completed NCT02581124 - Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease Phase 1
Completed NCT02268994 - KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD Phase 3
Completed NCT04543812 - PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKD Phase 3
Recruiting NCT05900635 - Effect of Adding Lactoferrin on Oral Iron on Anemia in Chronic Kidney Disease Patients Phase 4
Completed NCT04667533 - Desidustat in the Treatment of Chemotherapy Induced Anemia Phase 1
Completed NCT03731741 - Does Oral Pentoxifylline Administration Improve Hemoglobin in Hemodialysis Patients? Phase 2
Completed NCT02787824 - Periodic Versus Continuous IV Iron Supplementation in HD Patients Phase 4
Completed NCT03431623 - CKD-11101 Phase 3 SC Study Phase 3
Recruiting NCT01532349 - Vitamin D as a Modifier of Serum Hepcidin in Children With Chronic Kidney Disease Phase 2
Completed NCT05698420 - Investigation of the Effects of Medium Cut-off Dialyzers Versus High-Flux Dialyzers on Clinical and Laboratory Parameters of Prevalent Hemodialysis Patients
Completed NCT03427801 - Effect of Erythropoiesis-Stimulating Agent Therapy in Patients Receiving Palliative Care of Chronic Kidney Disease
Recruiting NCT03521713 - To Evaluate the Efficacy, Safety, and Immunogenicity of Subcutaneous Eporon Versus Epoetin Alfa (Eprex) Phase 3
Active, not recruiting NCT02754167 - Phase Ib Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients Phase 1/Phase 2
Completed NCT02805244 - Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis Phase 1
Completed NCT03428594 - CKD-11101 Phase 3 IV Study in Patients Who Had Renal Anemia Receiving Hemodialysis Phase 3
Not yet recruiting NCT06352138 - Comparative Study of Two Recombinant Human Erythropoietin Products on Chronic Kidney Disease Patients Phase 3
Suspended NCT05082584 - Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents Phase 3